BriaCell Therapeutics Corp. Warrant (BCTXZ) は上場企業です ヘルスケア セクターの バイオテクノロジー 業界で事業展開. 本社所在地は West Vancouver, BC, カナダ. 現CEOは William V. Williams.
BCTXZ を有する IPO日 2025-04-25, 16 名の正社員, に上場 NASDAQ Global Select, 時価総額 $244.89K.
BriaCell Therapeutics Corp., an immuno-oncology-focused biotechnology company, engages in developing immunotherapies for the management of cancer. Its lead drug candidate is Bria-IMT, a whole-cell cancer vaccine that is in Phase I/IIa clinical trials in combination with the immunotherapy development candidates retifanlimab. The company is also developing Bria-OTS, an off-the-shelf personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test that determines the patients' HLA types. It has a non-exclusive clinical trial collaboration with Incyte Corporation to evaluate the effects of combinations of novel clinical candidates; and a cooperative research and development agreement with the National Cancer Institute to conduct preclinical studies to develop and test Bria-OTS cellular immunotherapy as a treatment for cancer. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.
